{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:44Z","timestamp":1792812704861,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"novartis pharma ag, basel, switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To investigate the efficacy of secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) grouped by disease activity as assessed by C-reactive protein (CRP) levels and\/or magnetic resonance imaging (MRI) scores, human leukocyte antigen (HLA)-B27 status, and sex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The phase III PREVENT study randomized (1:1:1) 555 patients to receive subcutaneous secukinumab 150\u2009mg with (LD) or without (NL) loading dose or placebo weekly, followed by every 4\u2009weeks starting at week 4. Here, we report the results of a post hoc analysis reporting the efficacy outcomes (pooled secukinumab) to 16\u2009weeks by CRP, MRI, HLA-B27, and sex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Efficacy differences between the secukinumab and the placebo groups were highest in the CRP+, MRI+, HLA-B27+, and male subgroups, particularly for Ankylosing Spondylitis Disease Activity Score-CRP inactive disease and Assessment of SpondyloArthritis international Society (ASAS) partial remission outcomes. ASAS40 response rates in the CRP+\/MRI+ subgroup was 52.3% (secukinumab) versus 21.8% (placebo; <jats:italic>P<\/jats:italic> &lt; 0.0001) at week 16. ASAS40 response rates (secukinumab versus placebo) were 43.9% versus 32.6% in HLA-B27+, 32.7% versus 16.4% in HLA-B27\u2212 subgroups, 51.2% versus 30.8% in male, and 31.7% versus 25.3% in female patients, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Secukinumab improved the signs and symptoms of nr-axSpA across patients grouped by CRP (+\/\u2212) and\/or MRI (+\/\u2212) status, HLA-B27 (+\/\u2212) status, and sex. The highest treatment differences between secukinumab and placebo were observed in patients with both elevated CRP and evidence of sacroiliitis on MRI. Treatment difference was minimal between HLA-B27 (+) and (\u2212) subgroups. Male patients had higher relative responses than female patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02696031?term=NCT02696031&amp;draw=2&amp;rank=1\">NCT02696031<\/jats:ext-link>. Registered on 02 March 2016<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02613-9","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T07:02:42Z","timestamp":1630738962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5095","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Wiksten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian O.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Shete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno B.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Haemmerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"issue":"3","key":"2613_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.rdc.2012.09.003","volume":"38","author":"C Stolwijk","year":"2012","unstructured":"Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. Rheum Dis Clin N Am. 2012;38(3):441\u201376. https:\/\/doi.org\/10.1016\/j.rdc.2012.09.003.","journal-title":"Rheum Dis Clin N Am"},{"issue":"10089","key":"2613_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4.","journal-title":"Lancet."},{"issue":"5","key":"2613_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","volume":"75","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Strand V, Kay J, Braun J. The term \u2018non-radiographic axial spondyloarthritis\u2019 is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75(5):791\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208852.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2613_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.berh.2018.08.008","volume":"31","author":"MM Lockwood","year":"2017","unstructured":"Lockwood MM, Gensler LS. Nonradiographic axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2017;31(6):816\u201329. https:\/\/doi.org\/10.1016\/j.berh.2018.08.008.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"2613_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.rdc.2012.04.007","volume":"38","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M. Early spondyloarthritis. Rheum Dis Clin N Am. 2012;38(2):387\u2013403. https:\/\/doi.org\/10.1016\/j.rdc.2012.04.007.","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"2613_CR6","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","volume":"1","author":"J Sieper","year":"2015","unstructured":"Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1(1):15013. https:\/\/doi.org\/10.1038\/nrdp.2015.13.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2613_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13075-016-1027-9","volume":"18","author":"R Burgos-Varga","year":"2016","unstructured":"Burgos-Varga R, Wei JC, Rahman MU, Akkoc N, Haq SA, Hammoudeh M, et al. The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. Arthritis Res Ther. 2016;18(1):132. https:\/\/doi.org\/10.1186\/s13075-016-1027-9.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2613_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2018.1477591","volume":"14","author":"M Protopopov","year":"2018","unstructured":"Protopopov M, Poddubnyy D. Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol. 2018;14(6):525\u201333. https:\/\/doi.org\/10.1080\/1744666X.2018.1477591.","journal-title":"Expert Rev Clin Immunol"},{"key":"2613_CR9","doi-asserted-by":"publisher","first-page":"1824794","DOI":"10.1155\/2017\/1824794","volume":"2017","author":"AN Malaviya","year":"2017","unstructured":"Malaviya AN, Rawat R, Agrawal N, Patil NS. The nonradiographic axial spondyloarthritis, the radiographic axial spondyloarthritis, and ankylosing spondylitis: the tangled skein of rheumatology. Int J Rheumatol. 2017;2017:1824794.","journal-title":"Int J Rheumatol"},{"issue":"6","key":"2613_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","volume":"345","author":"JD Reveille","year":"2013","unstructured":"Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci. 2013;345(6):431\u20136. https:\/\/doi.org\/10.1097\/MAJ.0b013e318294457f.","journal-title":"Am J Med Sci"},{"key":"2613_CR11","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/rheumatology\/kez090","volume":"58","author":"I Redeker","year":"2019","unstructured":"Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, et al. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology (Oxford). 2019;58:1634\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"2613_CR12","first-page":"2283","volume":"54","author":"MP Sykes","year":"2015","unstructured":"Sykes MP. Doll H, Sengupta R, Gaffney Karl. Delay to diagnosis in axial spondyloarthritis: are we improving in the UK? Rheumatology (Oxford). 2015;54:2283\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"2613_CR13","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/ard.2010.145995","volume":"70","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, M\u00e4rker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369\u201374. https:\/\/doi.org\/10.1136\/ard.2010.145995.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2613_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/art.37803","volume":"65","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D. Review: Nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65(3):543\u201351. https:\/\/doi.org\/10.1002\/art.37803.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2613_CR15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2613_CR16","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Asim MK, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol (Hoboken). 2019;71(10):1599\u2013613. https:\/\/doi.org\/10.1002\/art.41042.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"26","key":"2613_CR17","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1505066.","journal-title":"N Engl J Med"},{"issue":"2","key":"2613_CR18","doi-asserted-by":"publisher","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","volume":"5","author":"X Baraliakos","year":"2019","unstructured":"Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5(2):e001005. https:\/\/doi.org\/10.1136\/rmdopen-2019-001005.","journal-title":"RMD Open"},{"issue":"6","key":"2613_CR19","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2665-9913(20)30066-7","volume":"2","author":"H Marzo-Ortega","year":"2020","unstructured":"Marzo-Ortega H, Sieper J, Kivitz AJ, Blanco R, Cohen M, Pavelka K, et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020;2(6):e339\u201346. https:\/\/doi.org\/10.1016\/S2665-9913(20)30066-7.","journal-title":"Lancet Rheumatol"},{"key":"2613_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilov\u00e1 E, Hall S, Kameda H, Kivitz AJ, et al. Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study. Arthritis Rheumatol (Hoboken). 2021;73:110\u201320.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"10217","key":"2613_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, \u00d8stergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(19)32971-X.","journal-title":"Lancet."},{"key":"2613_CR22","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"7","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol (Hoboken). 2015;7:2702\u201312.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"1","key":"2613_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-018-1665-1","volume":"20","author":"A Deminger","year":"2018","unstructured":"Deminger A, Klingberg E, Geijer M, G\u00f6thlin J, Hedberg M, Rehnberg E, et al. A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis. Arthritis Res Ther. 2018;20(1):162. https:\/\/doi.org\/10.1186\/s13075-018-1665-1.","journal-title":"Arthritis Res Ther"},{"key":"2613_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13075-018-1705-x","volume":"20","author":"A Ortolan","year":"2018","unstructured":"Ortolan A, van Lunteren M, Ramiro S, Ramonda R, Landew\u00e9 RBM, Dagfinrud H, et al. Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. Arthritis Res Ther. 2018;20:218.","journal-title":"Arthritis Res Ther"},{"key":"2613_CR25","first-page":"419","volume":"55","author":"C Webers","year":"2016","unstructured":"Webers C, Essers I, Ramiro S, Stolwijk C, Landew\u00e9 R, van der Heijde D, et al. Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatology (Oxford). 2016;55:419\u201328.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2613_CR26","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","volume":"75","author":"WP Maksymowych","year":"2016","unstructured":"Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Ann Rheum Dis. 2016;75(7):1328\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207596.","journal-title":"Ann Rheum Dis"},{"key":"2613_CR27","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (Hoboken). 2014;66:2091\u2013102.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"6","key":"2613_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201766.","journal-title":"Ann Rheum Dis"},{"key":"2613_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","volume":"55","author":"D van der Heijde","year":"2016","unstructured":"van der Heijde D, Joshi A, Pangan AL, Chen N, Betts K, Mittal M, et al. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2016;55:80\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2613_CR30","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1136\/ard.2011.152975","volume":"70","author":"HY Chung","year":"2011","unstructured":"Chung HY, Machado P, van der Heijde D, D\u2019Agostino MA, Dougados M. HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Ann Rheum Dis. 2011;70(11):1930\u20136. https:\/\/doi.org\/10.1136\/ard.2011.152975.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2613_CR31","doi-asserted-by":"publisher","first-page":"e000917","DOI":"10.1136\/rmdopen-2019-000917","volume":"5","author":"J Sieper","year":"2019","unstructured":"Sieper J, Landew\u00e9 R, Magrey M, Anderson JK, Zhong S, Wang X, et al. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open. 2019;5(1):e000917. https:\/\/doi.org\/10.1136\/rmdopen-2019-000917.","journal-title":"RMD Open"},{"key":"2613_CR32","doi-asserted-by":"publisher","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","DOI":"10.1001\/jama.2013.281053"},{"issue":"10","key":"2613_CR33","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG, Landew\u00e9 R, van der Heijde D, Baraliakos X, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis. 2009;68(10):1520\u20137. https:\/\/doi.org\/10.1136\/ard.2009.110767.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2613_CR34","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/ard.2010.147033","volume":"70","author":"IH Song","year":"2011","unstructured":"Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis. 2011;70(7):1257\u201363. https:\/\/doi.org\/10.1136\/ard.2010.147033.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2613_CR35","doi-asserted-by":"publisher","first-page":"e000749","DOI":"10.1136\/rmdopen-2018-000749","volume":"4","author":"J Braun","year":"2018","unstructured":"Braun J, Deodhar A, Landew\u00e9 R, Baraliakos X, Miceli-Richard C, Sieper J, et al. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open. 2018;4(2):e000749. https:\/\/doi.org\/10.1136\/rmdopen-2018-000749.","journal-title":"RMD Open"},{"issue":"8","key":"2613_CR36","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3899\/jrheum.141278","volume":"42","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J Rheumatol. 2015;42(8):1418\u201326. https:\/\/doi.org\/10.3899\/jrheum.141278.","journal-title":"J Rheumatol"},{"issue":"4","key":"2613_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3899\/jrheum.170166","volume":"45","author":"M Hebeisen","year":"2018","unstructured":"Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, et al. Response to tumor necrosis factor inhibition in male and female patients with ankylosing spondylitis: data from a Swiss cohort. J Rheumatol. 2018;45(4):506\u201312. https:\/\/doi.org\/10.3899\/jrheum.170166.","journal-title":"J Rheumatol"},{"issue":"7","key":"2613_CR38","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/annrheumdis-2017-211313","volume":"77","author":"MA Brown","year":"2018","unstructured":"Brown MA, Bird PA, Robinson PC, Mease PJ, van den Bosch F, Surian C, et al. Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. Ann Rheum Dis. 2018;77(7):1091\u20133. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211313.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02613-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02613-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02613-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T19:22:47Z","timestamp":1630783367000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02613-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2613"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02613-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,4]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the independent ethics committee or institutional review board for each participating center. The study was conducted according to the International Council for Harmonization E6 Guideline for Good Clinical Practice that has its origin in the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JB reports grant\/research support from AbbVie, Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD, Mundipharma, Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB; consultation fees from AbbVie, Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD, Mundipharma, Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB; and speakers bureau fees from AbbVie, Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD, Mundipharma, Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB. RB reports research grants from AbbVie, MSD, and Roche; consulting fees from AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD; and speakers bureau fees from AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, MSD, and Eli Lilly. HMO reports grant\/research support from Janssen and Novartis; is a consultant for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, and UCB; and received speakers\u2019 bureau fees from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB. LSG reports grant\/research support from UCB, AbbVie, Amgen, Novartis, and Pfizer and consulting fees from Galapagos, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. FVDB reports research grants, consultancy fees, or speaker honoraria from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SH reports consulting or speaking fees from Novartis, Merck, Janssen, Pfizer, Eli Lilly, and UCB and research grants from AbbVie, UCB, Janssen, and Merck. HK reports grant\/research support from AbbVie, Asahi-Kasei, Chugai, Eisai, Mitsubishi-Tanabe, and Novartis; consulting fees from AbbVie, Boehringer, Celgene, Eli Lilly, Janssen, Novartis, Sanofi, and UCB; and received speakers\u2019 bureau fees from AbbVie, Asahi-Kasei, BMS, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Novartis, and Pfizer. DP reports research grants from AbbVie, Eli Lilly, MSD, Novartis, and Pfizer; consultation fees from AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer, UCB, and Celgene; and speaker fees from AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer, UCB, and Roche. MVDS reports grant\/research support from Novartis, Eli Lilly, Boehringer Ingelheim, Janssen, and UCB; consultant fees from AbbVie, Novartis, Eli Lily, and MSD; and speaker fees from Novartis and MSD. ASW, BOP, AS, HBS, and SH are employees of Novartis and own Novartis stock. AD reports receiving honoraria for consulting or speaking for or research grants from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, GSK, Janssen, Novartis, Pfizer, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}